Reply to 'A phase II randomized controlled trial of nicotinamide for skin cancer chemoprevention in renal transplant recipients'.

O Yélamos, A C Halpern, M A Weinstock

Journal: The British journal of dermatology 2017;176(2):551-552

PMID: 27880000

Full Text on Ovid Technologies, Inc. View on PubMed

Abstract

Address: Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, NY, U.S.A.; Center for Dermatoepidemiology, Veterans Affairs Medical Center, Providence, RI, U.S.A.; Department of Dermatology, Rhode Island Hospital, Providence, RI, U.S.A.; Departments of Dermatology and Epidemiology, Brown University, Providence, RI, U.S.A.

DOI: 10.1111/bjd.15203

Link outs

Free resources

Medical:

https://medlineplus.gov/kidneytransplantation.html

Other Literature Sources:

https://scite.ai/reports/27880000

Subscription / membership required

Full Text Sources:

http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=linko...
https://doi.org/10.1111/bjd.15203
https://academic.oup.com/bjd/article-lookup/doi/10...

MeSH Terms: Chemoprevention, Humans, Kidney Transplantation, Niacinamide, Skin Neoplasms, Transplant Recipients